HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma.
Turab MohammedShaunak MangeshkarAakash DesaiUpendra HegdePublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
The metastatic MEC in our patient overexpressed HER-2 Neu. Owing to Trastuzumab and Pertuzumab response, Trastuzumab emtansine (TDM-1) was initiated on a compassionate basis which further extended the survival but had to be terminated owing to adverse effects. Given the paucity of data on targeted therapies in the treatment of metastatic SGNs and the safety, tolerability, and efficacy of TDM-1 therapy among the elderly, further studies are warranted to answer these important questions and to identify eligible patients for this novel treatment option.
Keyphrases
- squamous cell carcinoma
- small cell lung cancer
- epidermal growth factor receptor
- metastatic breast cancer
- end stage renal disease
- chronic kidney disease
- machine learning
- stem cells
- genome wide
- clinical trial
- case report
- gene expression
- prognostic factors
- mesenchymal stem cells
- combination therapy
- dna methylation
- artificial intelligence
- big data
- tyrosine kinase
- cell therapy